KR102329796B1 - 종양세포 치사활성 및 항균성 조성물 및 방법 - Google Patents

종양세포 치사활성 및 항균성 조성물 및 방법 Download PDF

Info

Publication number
KR102329796B1
KR102329796B1 KR1020167014198A KR20167014198A KR102329796B1 KR 102329796 B1 KR102329796 B1 KR 102329796B1 KR 1020167014198 A KR1020167014198 A KR 1020167014198A KR 20167014198 A KR20167014198 A KR 20167014198A KR 102329796 B1 KR102329796 B1 KR 102329796B1
Authority
KR
South Korea
Prior art keywords
cells
pharmaceutical composition
exosomes
microvesicles
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167014198A
Other languages
English (en)
Korean (ko)
Other versions
KR20160068976A (ko
Inventor
한스 쥐. 클링거만
배리 제이. 시몬
Original Assignee
이뮤너티바이오, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 이뮤너티바이오, 인크. filed Critical 이뮤너티바이오, 인크.
Priority to KR1020217037585A priority Critical patent/KR102476640B1/ko
Publication of KR20160068976A publication Critical patent/KR20160068976A/ko
Application granted granted Critical
Publication of KR102329796B1 publication Critical patent/KR102329796B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/44—Fungal antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5063—Compounds of unknown constitution, e.g. material from plants or animals
    • A61K9/5068—Cell membranes or bacterial membranes enclosing drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C12N2500/32—Amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2509/00—Methods for the dissociation of cells, e.g. specific use of enzymes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/70—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in livestock or poultry

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Botany (AREA)
  • Developmental Biology & Embryology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
KR1020167014198A 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법 Active KR102329796B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217037585A KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361899066P 2013-11-01 2013-11-01
US61/899,066 2013-11-01
PCT/US2014/062695 WO2015066054A1 (en) 2013-11-01 2014-10-28 Tumoricidal and antimicrobial compositions and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217037585A Division KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20160068976A KR20160068976A (ko) 2016-06-15
KR102329796B1 true KR102329796B1 (ko) 2021-11-23

Family

ID=53005034

Family Applications (5)

Application Number Title Priority Date Filing Date
KR1020167014198A Active KR102329796B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020217037585A Active KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020237018562A Ceased KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020257021166A Pending KR20250099421A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020227036373A Ceased KR20220147705A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Family Applications After (4)

Application Number Title Priority Date Filing Date
KR1020217037585A Active KR102476640B1 (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020237018562A Ceased KR20230085215A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020257021166A Pending KR20250099421A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법
KR1020227036373A Ceased KR20220147705A (ko) 2013-11-01 2014-10-28 종양세포 치사활성 및 항균성 조성물 및 방법

Country Status (9)

Country Link
US (10) US10258649B2 (https=)
EP (4) EP4134085B1 (https=)
JP (2) JP6603216B2 (https=)
KR (5) KR102329796B1 (https=)
CN (3) CN121466286A (https=)
AU (1) AU2014342477B2 (https=)
CA (1) CA2927977C (https=)
ES (1) ES2935906T3 (https=)
WO (1) WO2015066054A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4134085B1 (en) 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
EP4424326A3 (en) 2015-06-10 2024-11-13 ImmunityBio, Inc. Modified nk-92 cells for treating cancer
WO2017100709A1 (en) * 2015-12-09 2017-06-15 Nant Holdings Ip, Llc Compositions and methods for treatment of her2 positive metastatic breast cancer
US11142552B2 (en) * 2016-07-19 2021-10-12 National Institute Of Plant Genome Research Protein against fungal pathogens
WO2018064594A2 (en) * 2016-09-29 2018-04-05 Nantkwest, Inc. Hla class i-deficient nk-92 cells with decreased immunogenicity
CN108324735B (zh) * 2017-01-20 2024-02-09 李莉 用于疾病治疗的胞外体制剂及其应用
US20200163993A1 (en) * 2017-05-09 2020-05-28 Saint Louis University Treatment of cancer and infectious diseases with natural killer (nk) cell-derived exosomes
US20210040451A1 (en) * 2018-01-31 2021-02-11 Nantkwest, Inc. Use of 5% human albumin in wash and harvest media
CN108815186A (zh) * 2018-06-14 2018-11-16 上海鸣大生物科技有限公司 一种治疗hpv持续感染引起疾病的药物及制备方法与应用
EP4013782A4 (en) * 2019-08-12 2023-12-27 Advaccine (Suzhou) Biopharmaceuticals Co. Ltd. IMMUNE COMPOSITION COMPRISING A RESPIRATORY SYNCYTIAL VIRUS (RSV) POLYPEPTIDE G
WO2025221993A1 (en) 2024-04-18 2025-10-23 Immunitybio, Inc. Compositions and methods for producing il-16
US20260027155A1 (en) 2024-07-23 2026-01-29 Immunitybio, Inc. Compositions and methods related to potent cytotoxic m-cenk cells from cd3/cd14-depleted apheresis products

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018183A1 (en) * 1997-04-30 2004-01-29 Hans Klingemann Modified natural killer cell lines and methods of use

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8034332B2 (en) 1997-04-30 2011-10-11 Conkwest, Inc. Interleukin-secreting natural killer cell lines and methods of use
US8067044B2 (en) 2004-02-13 2011-11-29 Cognis France S.A.S. Cosmetic compositions containing an extract of leaves of the Castanea sativa plant and cosmetic treatments
WO2006004518A1 (en) 2004-07-02 2006-01-12 Avaris Ab Method for the genetic activation of cells and uses of said cells
DE602005016683D1 (de) 2004-07-10 2009-10-29 Fox Chase Cancer Ct Genetisch modifizierte, menschliche, natürliche killerzellenlinien:
JP2008539753A (ja) 2005-05-09 2008-11-20 グリクアート バイオテクノロジー アクチェンゲゼルシャフト 修飾ｆｃ領域およびｆｃ受容体との結合変更を有する抗原結合分子
CN102014934B (zh) 2008-02-22 2014-08-20 新加坡科技研究局 间充质干细胞颗粒
WO2012013204A1 (en) * 2010-07-28 2012-02-02 Canvax Biotech Sl Novel ultrasensitive cell based sensors and uses thereof
KR101298012B1 (ko) 2011-02-08 2013-08-26 (주)차바이오앤디오스텍 암세포로의 표적지향을 위한 자연살해 세포를 포함하는 림프구의 제조방법 및 이를 포함하는 약학 조성물
US20150212064A1 (en) * 2011-08-12 2015-07-30 The Childrens's Hospital Of Philadelphia Degranulation indicator and methods of use thereof
EP4134085B1 (en) 2013-11-01 2026-04-29 ImmunityBio, Inc. Tumoricidal and antimicrobial compositions and methods
JP2020524164A (ja) 2017-06-20 2020-08-13 ナントクエスト インコーポレイテッド Ｎｋ−９２細胞を用いてメルケル細胞癌（ｍｃｃ）を治療するための方法
KR20200035999A (ko) 2017-08-04 2020-04-06 난트케이웨스트, 인크. Nk-92 세포를 이용한 백혈병의 치료 및 억제

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040018183A1 (en) * 1997-04-30 2004-01-29 Hans Klingemann Modified natural killer cell lines and methods of use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
THE JOURNAL OF IMMUNOLOGY, Vol. 189, No. 6, pp. 2833-2842 (2012)*

Also Published As

Publication number Publication date
KR20250099421A (ko) 2025-07-01
CA2927977C (en) 2024-03-05
US20160250256A1 (en) 2016-09-01
US20190192568A1 (en) 2019-06-27
KR20230085215A (ko) 2023-06-13
US10772912B2 (en) 2020-09-15
CN120501764A (zh) 2025-08-19
JP2020073478A (ja) 2020-05-14
US11304977B2 (en) 2022-04-19
JP6603216B2 (ja) 2019-11-06
EP4134085B1 (en) 2026-04-29
US20250170181A1 (en) 2025-05-29
JP2016539105A (ja) 2016-12-15
US10646516B2 (en) 2020-05-12
US20200038445A1 (en) 2020-02-06
US11213547B2 (en) 2022-01-04
US20190125801A1 (en) 2019-05-02
EP4134085A1 (en) 2023-02-15
JP6870053B2 (ja) 2021-05-12
US10517895B2 (en) 2019-12-31
EP3062800A4 (en) 2017-04-19
EP3062800B1 (en) 2020-04-08
KR20210144920A (ko) 2021-11-30
US20190192569A1 (en) 2019-06-27
CN105848662A (zh) 2016-08-10
AU2014342477A1 (en) 2016-05-26
US20220160768A1 (en) 2022-05-26
ES2935906T3 (es) 2023-03-13
WO2015066054A1 (en) 2015-05-07
CA2927977A1 (en) 2015-05-07
US11975027B2 (en) 2024-05-07
US12064450B2 (en) 2024-08-20
EP3062800A1 (en) 2016-09-07
US20190192570A1 (en) 2019-06-27
EP3701957A1 (en) 2020-09-02
CN121466286A (zh) 2026-02-06
US20240366674A1 (en) 2024-11-07
US20220175838A1 (en) 2022-06-09
EP3701957B1 (en) 2022-12-28
KR20160068976A (ko) 2016-06-15
AU2014342477B2 (en) 2019-08-01
KR102476640B1 (ko) 2022-12-09
US10258649B2 (en) 2019-04-16
EP4707383A2 (en) 2026-03-11
KR20220147705A (ko) 2022-11-03

Similar Documents

Publication Publication Date Title
US12064450B2 (en) Tumoricidal and antimicrobial compositions and methods
ES2877099T3 (es) Beta-glucano en combinación con agentes anticáncer que afectan al microambiente tumoral
KR20220158640A (ko) 리포펩타이드와 폴리(i:c) 아쥬번트를 이용하는 면역항암치료제 조성물
HK40129528A (zh) 杀肿瘤和抗微生物组合物和方法
HK1228299B (en) Tumoricidal compositions
HK1228299A1 (en) Tumoricidal compositions

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20160527

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20191018

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201216

Patent event code: PE09021S01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20210622

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20201216

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

X091 Application refused [patent]
AMND Amendment
PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20210622

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20210216

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20191018

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20210817

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20210723

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210622

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20210216

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20191018

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
A107 Divisional application of patent
GRNT Written decision to grant
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20211117

PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211117

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211118

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20241107

Start annual number: 4

End annual number: 4